The pharmaceutical industry has experienced an extraordinary rise in the generation and use of enormous datasets. Nevertheless, there remain great challenges on this front regarding everything from target identification to understanding the performance of marketed products. In the context of this broad impact, we have assembled a group of leading researchers and executives from the MIT-connected community who will address questions of discovery, data integration, and system perturbation analysis, including use of artificial intelligence and machine learning techniques. What is the impact of current developments on high-throughput profiling, computational biology, and validation of gene targets? How do these developments impact the use of chemical libraries, drug-delivery systems, and patient-facing objectives? These are the types of questions that will be addressed in this exciting panel discussion.
Mark Bathe Associate Professor of Biological Engineering, MIT BE
Oral Buyukozturk MIT Professor of Civil & Environmental Engineering
Thomas Heldt Assistant Professor of Electrical & Biomedical Engineering
Contact
Assistant
The next generation of energy storage, sensors and neuromorphic computer logics in electronics rely largely on solving fundamental questions of mass and charge transport of ionic carriers and defects in materials and their structures. Here, understanding the defect kinetics in the solid state material building blocks and their interfaces with respect to lattice, charge carrier types and interfacial strains are the prerequisite to design novel energy storage, sensing and computing functions. Through this presentation basic theory and model experiments for solid state oxides their impedances and memristance, electro-chemo-mechanics and lattice strain modulations is being discussed as a new route for engineering material and properties on the examples of solid state batteries, environmental CO2 sensors and memristors for memory and neuromorphic computing chips. Central are the making of new oxide film materials components, and manipulation of the charge carrier transfer and defect chemistry (based on ionic and electronic carriers), which alter directly the device performances and new operation metrics.
Over the past decade, research on the development of multi-cellular engineered living systems has produced technologies and capabilities that are now positioned to facilitate a fundamental understanding of disease processes and can help to identify innovative therapeutic strategies. Globally, while many labs are engaged in the development of new and more sophisticated organ models for drug discovery and screening, there is an urgent need to disrupt the way drugs are currently developed. Our vision is to humanize drug development based on a new approach that integrates microphysiological system models of disease and enhanced model control/interrogation, with modern systems biology and systems immunology. This is the focus of Living Machines, one of five threads in the New Engineering Education Transformation (NEET) program to reimagine engineering education at MIT in which sophomores, juniors and seniors, under the guidance of faculty mentors and instructors, learn, discover, build and engineer living systems for broad applications in biotechnology and medical devices. This webinar will share the perspectives of 3 MIT faculty, their research capabilities and interests in which NEET students can participate, and that of several NEET students and what they can or hope to achieve.
Cagri Hakan Zaman Lecturer, MIT Department of Architecture